Business
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent
About this update from Glucotrack, Inc.
[{"type":"text","content":"Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s implantablecontinuous blood glucose monitoring (CBGM) technology, strengthening the Company’sintellectual property portfolio Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2025. “In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation. We strengthened our competitive position with three new patents issued by the USPTO and continued to work closely with the FDA on alignment as we progress toward securing IDE approval and initiating our U.S. clinical study program of our CBGM product,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We entered 2026 with strong momentum and a reinforced balance sheet, positioning the Company to execute on important development and regulatory milestones.” Fourth Quarter 2025 & Recent Highlights Corporate Highlights ●Completed $4.0 million private placement. ○In December 2025, the Company entered into a securities purchase agreement with a single institutional investor for the sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at a combined effective price of $3.87 per share and accompanying warrant, resulting in aggregate gross proceeds of approximately $4.0 million before fees and expenses. ○The Company expects to use the net proceeds from the offering for working capital and general corporate purposes. ●Strengthened the Company’s intellectual property portfolio for novel implantable CBGM platform. The three patents protect key technologies in Glucotrack’s CBGM system, a long-term implantable device designed for three-year sensor longevity, including proprietary sensor chemistry, intravascular lead design, and low-...